Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name Olaratumab
Trade Name Lartruvo
Synonyms IMC-3G3
Drug Descriptions

Lartruvo (olaratumab) is a monoclonal antibody that targets PDGFR-alpha and prevents ligand binding, potentially leading to decreased angiogenesis and reduced proliferation of tumor cells (PMID: 27291997). Lartruvo (olaratumab) in combination with doxorubicin is FDA approved for patients with soft tissue sarcoma (FDA.gov).

DrugClasses PDGFRA Antibody 2
CAS Registry Number 1024603-93-7
NCIT ID C79825

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Doxorubicin + Ifosfamide + Mesna + Olaratumab Doxorubicin Ifosfamide Mesna Olaratumab 0 1
Doxorubicin + Olaratumab Doxorubicin Olaratumab 0 2
Doxorubicin + Olaratumab + Sotigalimab Doxorubicin Olaratumab Sotigalimab 0 1
Doxorubicin + Olaratumab + Trabectedin Doxorubicin Olaratumab Trabectedin 0 1
Gemcitabine + Nab-paclitaxel + Olaratumab Gemcitabine Nab-paclitaxel Olaratumab 0 1
Olaratumab Olaratumab 0 5
Olaratumab + Pembrolizumab Olaratumab Pembrolizumab 0 1


Additional content available in CKB BOOST